Phosphodiesterase inhibitors.

Article Details

Citation

Copy to clipboard

Boswell-Smith V, Spina D, Page CP

Phosphodiesterase inhibitors.

Br J Pharmacol. 2006 Jan;147 Suppl 1:S252-7. doi: 10.1038/sj.bjp.0706495.

PubMed ID

16402111 [ View in PubMed

]

Abstract

Phosphodiesterases are a diverse family of enzymes that hydrolyse cyclic nucleotides and thus play a key role in regulating intracellular levels of the second messengers cAMP and cGMP, and hence cell function. Theophylline and papaverine have historically been used therapeutically and are known to be weak inhibitors of PDE, but to what extent this contributed toward their clinical efficacy was poorly defined. However, the discovery of 11 isoenzyme families and our increased understanding of their function at the cell and molecular level provides an impetus for the development of isoenzyme selective inhibitors for the treatment of various diseases. This review focuses on the development of PDE3 inhibitors for congestive heart failure, PDE4 inhibitors for inflammatory airways disease and most successfully, PDE5 inhibitors for erectile dysfunction.

DrugBank Data that Cites this Article

Drugs

Caffeine

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Caffeine	Phosphodiesterase enzymes (Protein Group)	Protein group	Humans	Yes	Inhibitor	Details